Table 2.
Socio-demographic and clinical characteristics of the participants and BDNF correlation between these groups.
| GROUPS |
TOTAL PATIENTS*
(N=80) n (%) |
CONTROL GROUP* (N=13) n (%) | p1 value | p2 value |
|---|---|---|---|---|
| Socio-demographic value1 | ||||
| Gender (Female) | 45 (56.3) | 7 (53.8) | n.s. | n.s. |
| Education | - | - | ˂0.001# | χ2=10.4, 0.016€ |
| Primary and literate | 27 (33.75) | - | - | - |
| Middle School | 12 (15.0) | 1 (7.7) | - | - |
| High School | 28 (35.0) | 2 (15.4) | - | - |
| University | 12 (15.0) | 10 (76.9) | - | - |
| Marital status (Married) | 32 (40.0) | 9 (69.2) | χ2=3.876, 0.049 | n.s. |
| Economical situation (Medium) | 67 (84.6) | 13 (100.0) | n.s. | n.s. |
| Smokıng (Yes) | 12 (14.1) | 5 (38.5) | n.s. | n.s. |
| Clinical characteristics value1 | ||||
| Treatment (Polytherapy) | 46 (57.5) | - | n.s. | n.s. |
| Other drug use (Yes) | 44 (47.3) | - | n.s. | n.s. |
| Accompanying diseases (Yes) | 38 (40.9) | n.s. | n.s. | |
| Epilepsy type (Focal) | 58 (72.5) | - | n.s. | t=2.538, 0.013 |
| Etiology | - | - | n.s | n.s |
| Genetic | 18 (22.5) | - | - | - |
| Structural/Metabolic | 38 (47.5) | - | - | - |
| Unknown cause | 24 (30.0) | - | - | - |
| Syndromes | - | - | n.s | n.s |
| Unknown cause | 23 (28.2) | - | - | - |
| Perinatal Trauma | 10 (12.8) | - | - | - |
| Trauma | 6 (7.7) | - | - | - |
| Infection | 2 (2.6) | - | - | - |
| Tumor | 5 (6.4) | - | - | - |
| MCD (Hemimegalencephaly etc.) | 5 (6.4) | - | - | - |
| MTLE | 13 (15.4) | - | - | - |
| Reflex Epilepsies | 1 (1.3) | - | - | - |
| EWGTCSA | 3 (3.8) | - | - | - |
| JME | 7 (9.0) | - | - | - |
| JAE | 2 (2.6) | - | - | - |
| LKS | 1 (1.3) | - | - | - |
| BECTS | 1 (1.3) | - | - | - |
| CAE | 1 (1.3) | - | - | - |
| Number of seizure | - | - | n.s | n.s |
| Less than 1 year | 30 (37.5) | - | - | - |
| More than a month | 28 (35.0) | - | - | - |
| 1 month - 1 year | 22 (27.5) | - | - | - |
1Significant value of total with control group for socio-demographic and compoatiion between variable groups e.g. focal/generalize for clinical characteristic in the maingroups and in the subgroups. 2Comparation between variable groups e.g. female/male for BDNF values. *Data are expressed as a percentage. # Freeman Halton Test. € Kruskall Wallis test, the highest is primary and literate also the others. M; Medium, MCD; Malformations of cortical development, MTLE; Mesial Temporal Lope Epilepsy, EWGTCSA; Epilepsy with generalized tonic-clonic seizures alone, JME; Juvenile myoclonic epilepsy, JAE; Juvenile absence epilepsy, LKS; Landau-Klefiner syndrome, BECTS; Benign epilepsy with centrotemporal spikes, CAE; Childhood absence epilepsy. Without impairment of consciousness or awareness; WOMAC; With observable motor or automatic components. WICA; With impairment of consciousness or awareness, EBCS;Evolving to a bilateral, convulsive seizure, GSTC; Generalized Seizures Tonic Clonic, BDNF; brain-derived neurotropic factor, n.s.: not significant.